Production (Stage)
D
Beam Therapeutics Inc. BEAM
$16.83 -$0.41-2.38% NASDAQ
Recommendation
Prev Close
$16.83
Volume
962,382
Avg Vol (90D)
2,023,730
Market Cap
$1.64B
Dividend & Yield
--
52-Week Range
$13.53 - $35.25
P/E (TTM)
--
EPS (TTM)
-$4.62
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)
5/25/2025 - TipRanks Financial Blog
Beam Therapeutics (BEAM, $17.22) entered Downtrend as Momentum indicator drops below 0 level on May 22, 2025
5/23/2025 - Tickeron - Stocks
Twinbeech Capital LP Purchases 69,456 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
5/23/2025 - MarketBeat
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
5/22/2025 - Zacks Investment Research
Rafferty Asset Management LLC Has $2.76 Million Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
5/22/2025 - MarketBeat
Point72 Asset Management L.P. Buys Shares of 193,356 Beam Therapeutics Inc. (NASDAQ:BEAM)
5/22/2025 - MarketBeat
Beam Therapeutics (BEAM, $17.75) entered Uptrend as Momentum indicator ascends above 0 level on May 20, 2025
5/21/2025 - Tickeron - Technical Analysis
3 Top Genomics Stocks to Add to Your Portfolio in 2025
5/21/2025 - Zacks Investment Research
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Tang Capital Management LLC
5/20/2025 - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Tang Capital Management LLC
5/18/2025 - Ticker Report
Polar Asset Management Partners Inc. Acquires 187,455 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
5/18/2025 - MarketBeat
Hudson Bay Capital Management LP Sells 15,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
5/16/2025 - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust Corp
5/16/2025 - MarketBeat
Bank of America Securities Remains a Buy on Beam Therapeutics (BEAM)
5/15/2025 - TipRanks Financial Blog
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at ...
5/14/2025 - GuruFocus
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at ...
5/14/2025 - GuruFocus
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
5/14/2025 - Globe Newswire
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
5/13/2025 - GuruFocus
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
5/13/2025 - Globe Newswire
Beam Therapeutics (BEAM, $18.24) Moving Average Convergence Divergence (MACD) Histogram turned positive on May 12, 2025
5/13/2025 - Tickeron - Stocks
HC Wainwright Issues Positive Forecast for BEAM Earnings
5/13/2025 - MarketBeat
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation ...
5/12/2025 - GuruFocus
Beam Therapeutics (BEAM) Gains FDA RMAT Designation for BEAM-302 BEAM Stock News
5/12/2025 - GuruFocus
Beam Therapeutics granted FDA's Regenerative Medicine Advanced Therapy designation
5/12/2025 - Seeking Alpha - Healthcare
Beam Therapeutics announces FDA grants RMAT designation to BEAM-302
5/12/2025 - The Fly
Income Statement
Total Revenue (TTM)
$63.58M
EBITDA (TTM)
-$408.70M
EBIT (TTM)
-$430.72M
Net Income (TTM)
-$387.34M
Balance Sheet
Total Assets (Q)
$1.47B
Total Debt (Q)
$158.13M
Total Liabilities (Q)
$343.78M
Book Value Per Share (Q)
$11.52
Cash Flow
Cash from Operations (TTM)
-$351.38M
Cash from Investing (TTM)
$113.38M
Cash from Financing (TTM)
$478.22M
Net Change in Cash (TTM)
$240.22M
Filings
Filing Date
Tuesday, May 6, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
2.27
7-Day Total Return
-2.43%
30-Day Total Return
8.79%
60-Day Total Return
-36.10%
90-Day Total Return
-28.05%
Year to Date Total Return
-31.86%
1-Year Total Return
-30.80%
2-Year Total Return
-49.58%
3-Year Total Return
-46.47%
5-Year Total Return
-30.80%
52-week Low
Apr 07, 2025 - $13.53
52-week High
Feb 18, 2025 - $35.25
Valuation
Market Cap
$1.64B - Small Cap
Enterprise Value
$578.87M
Price/Sales (TTM)
23.29
Price/Book (Q)
1.46
Dividends and Shares
Shares Outstanding
87.98M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
beamtx.com
Phone Number
857 327 8775
Address
238 Main Street
Cambridge, MA 02142
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed